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TRPal (TRP) channels modulate intracellular Ca2+ concentrations, consequently
affecting both cell death and proliferation. It is not, therefore, surprising that the membrane expression of
some TRP channels is altered during tumor growth and metastasis. These variations in channel abundance
are due to TRP regulation on the transcriptional, translational, and targeting levels. This article mainly
reviews the transcriptional mechanisms modulating TRP expression during tumorigenesis, involving
hormones, growth factors, and alternative splicing.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionThe processes involved in the transformation of normal cells to
tumorigenic cells and tumor progression are complex and only partly
understood [1,2]. This transition is caused by the accumulation of
mutations in certain key signaling proteins, along with the formation
and selection by evolution of those cells capable of competing more
aggressively in their local environment and, in the case of metastatic
cells, in the environments of other organs. Some of the most
important signaling pathways altered in tumorigenesis enhance cell
proliferation and inhibit apoptosis. Ca2+ homeostasis controls these
cellular processes, including proliferation, apoptosis, gene transcrip-
tion, and angiogenesis [3]. Ca2+ signaling is, thus, required for cell
proliferation in all eukaryote cells, while some transformed cells and
tumor cell lines depend less on Ca2+ to maintain proliferation [4,5].
Furthermore, the regulation of cell cycles, apoptosis, or proliferation
depends on the amplitude and temporal–spatial aspects of the Ca2+
signal [6,7], thus highlighting the importance of Ca2+ signaling
components such as Ca2+ channels. Indeed dysfunctions in Ca2+
channels are involved in tumorigenesis, since increased expression of
plasma membrane Ca2+ channels ampliﬁes Ca2+ inﬂux with conse-
quent promotion of Ca2+-dependent proliferative pathways [3,6,8].
TRP (Transient Receptor Potential) channels contribute to changes
in intracellular Ca2+ concentrations, either by acting as Ca2+ entry
pathways in the plasma membrane or via changes in membrane
polarization, modulating the driving force for Ca2+ entry mediated by+33 320 43 40 66.
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ll rights reserved.alternative pathways [9]. In addition, TRP channels are expressed on
the membranes of internal Ca2+ stores [10–14], where theymay act as
triggers for enhanced proliferation, aberrant differentiation, and
impaired ability to die, leading to the uncontrolled expansion and
invasion characteristic of cancer. Indeed, in recent years, the extent to
which TRP channels are associated with cancer has been increasingly
clariﬁed. TRP proteins display an extraordinary diversity of functional
properties and have profound effects on a variety of physiological and
pathological conditions [9,15,16]. About approximately thirty TRPs
identiﬁed to date are classiﬁed in six different families: TRPC
(Canonical), TRPV (Vanilloid), TRPM (Melastatin), TRPML (Mucoli-
pin), TRPP (Polycystin), and TRPA (Ankyrin transmembrane protein)
[16]. The expression levels of members of the TRPC, TRPM, and TRPV
families are correlated with the emergence and/or progression of
certain epithelial cancers [17–20]. It has not yet been established
whether these expression changes are drivers, required to sustain the
transformed phenotype. Usually, the progression of cells from a
normal, differentiated state to a tumorigenic, metastatic state involves
the accumulation of mutations in multiple key signaling proteins,
encoded by oncogenes and tumor suppressor genes, together with the
evolution and clonal selection of more aggressive cell phenotypes.
These events are associated with changes in the expression of
numerous other proteins [21]. To date, most changes involving TRP
proteins do not involve mutations in the TRP gene, but rather
increased or decreased expression levels of the wild-type TRP protein,
depending on the stage of the cancer. Table 1 summarizes these
changes in cancer and metastatic cells, substantiating the absence of a
uniform TRP proﬁle for expression changes during carcinogenesis. On
the other hand, several of some common tuning pathways lead to this
Table 1
Expression proﬁle of TRPs in cancer
Channel Localization Cancer type Isoforms Expression Ref
Healthy/benign Tumor Invasive
TRPV1 PM Bladder Yes Yes ↓ Loss [75,89]
ERM Glioma Yes ↑
TRPV2 PM Bladder Full Yes ↑ ↑ [58]
Short Yes ↓ Loss
Prostate
TRPV6 PM Breast
Ovarian ND Yes ↑ ↑ [19,29,31,38]
Thyroid
Colon




TRPM8 PM Melanoma Yes Yes ↑ Loss [10,18,26,90]
ERM Lung
Colon
TRPC6 PM Breast Yes Yes ↑ ↑ [71, 91]
PM: Plasma membrane; ERM: Endoplasmic reticulum membrane; ND: Not deﬁned.
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regulated at different levels: (i) transcriptional and translational, (ii)
trafﬁcking of the channel to the plasma membrane, or (iii) directly on
plasma membrane stabilization. Modulation of TRP expression/
activity on one of these levels affects intracellular Ca2+ concentrations
and, consequently, the processes involved in carcinogenesis, such as
proliferation, apoptosis, and migration. The mechanisms described in
this review are depicted in Fig. 1. Here, we will focus on the
transcriptional regulation of TRPs during carcinogenesis and consider
their regulation by hormones and growth factors, which determine
the abundance of these proteins, as well as the alternative splicing,
which results in distinct spatial organization of the diverse isoforms in
cell membranes and determines the channel's functionality by a
dominant negative effect. We will hence consider examples of TRPs
regulation mechanisms in tumor cells and their signiﬁcance for the
maintenance of the cancer phenotype. Finally, we discuss the
prognostic and therapeutic opportunities opened up by the remodel-
ing of TRP channels in cancer.Fig. 1. Scheme summarizing the mechanisms through which TRP channels affect tumor gro
regulate the TRP channel transcription/translation, plasma membrane (PM) targeting and lo
entering the cell. These changes in intracellular Ca2+ concentration alter essential processe
hormone receptor; GFR: GF receptor.2. Hormonal regulation
Transcriptional regulation of proteins is often under hormonal
control. This is of particular interest in the case of the TRP channels
involved in hormone-dependent cancer, such as prostate and breast
cancers.
In the early stages, prostate cancer progression depends on
androgens for growth and survival, and, at this time, androgen
ablation therapy may cause tumor regression. In contrast, the later,
invasive stages of prostate cancer are androgen-independent [22].
Two TRP channels are regulated by androgens and seem to play a key
role in the progression of prostate cancer: TRPM8 and TRPV6.
TRPM8 expression increases in both benign prostate hyperplasia
and in prostate carcinoma cells, which both present high androgen
levels [18]. Anti-androgen therapy greatly reduces the expression of
TRPM8, conﬁrming that it is regulation by androgens [23]. Indeed,
trpm8 gene expression seems to be directly controlled by androgen
receptors [24,25], making it a primary androgen-response gene [24].wth and metastasis. Hormones, growth factors (GF) and alternative splicing isoforms
calization, as well as the channel activity, resulting in modiﬁcation of the Ca2+ amount
s in tumor growth and metastasis, such as proliferation, apoptosis and migration. HR:
955D. Gkika, N. Prevarskaya / Biochimica et Biophysica Acta 1793 (2009) 953–958Analysis of the trpm8 gene shows 10 putative androgen responsive
elements, one in the promoter region and the remainder in introns of
the gene [24,25]. Binding the testosterone androgen-receptor complex
to these androgen-responsive elements may initiate TRPM8 gene
transcription. Single-cell RT-PCR and immunohistochemical experi-
ments conducted on primary humanprostate cancer cells showed that
TRPM8 was mainly expressed in androgen-dependent, apical secre-
tory epithelial cells. Its expression was also down-regulated in cells
that lost androgen receptor activity and regressed to the basal
epithelial phenotype [24]. In prostate cancer, a signiﬁcant difference
has been also detected in TRPM8 mRNA expression levels between
malignant and non-malignant tissue specimens [26]. According to
Tsavaler's hypothesis [18], TRPM8 over-expression and over-activity in
circumscribed, androgen-dependent prostate cancers may be corre-
lated to the higher rate of growth of these cells compared to normal
ones [27,28]. Interestingly, during the transition to androgen inde-
pendence, TRPM8 disappeared from a xenograft prostate cancer
model. This was also the case in prostate cancer tissue from patients
treated preoperatively with anti-androgen therapy, suggesting that its
loss may be associated with a more advanced form of the disease [23].
Further, hormonal regulation by androgens apparently deﬁnes TRPM8
localization. Channel expression on the plasma or endoplasmic
reticulum (ER) membrane depends on the differentiation and
oncogenic status of prostate epithelial cells, probably mediated by
two isoforms that are differentially regulated by androgens [10] (for
more details see section 4). Highly-differentiated prostate epithelial
luminal cells express functional plasma membrane TRPM8, while ER
TRPM8 remains functional, irrespective of the prostate cells' differ-
entiation status [10]. Considering that ER Ca2+ content is known to
regulate cancer cell growth, the ﬁnding that ER TRPM8 is functional in
dedifferentiated prostate cancer cells with down-regulated androgen
receptors provides new insight into the role of this channel in prostate
cancer progression and may be of great importance in developing
therapeutic strategies for metastasized prostate cancer.
Less information is available on TRPV6 androgen hormonal
regulation in the prostate. TRPV6 expression in healthy and benign
human prostate tissue is very low or even undetectable and increases
with the aggressiveness of the cancer and the extent of metastasis
outside the prostate [29,30]. TRPV6 expression, therefore, is the
opposite to that of TRPM8, suggesting negative regulation by
androgens. Indeed, androgen treatment of the human Lymph Node
Prostate Cancer (LNCaP) cell line, which constitutively expresses the
trpv6 gene, reduces TRPV6 mRNA levels by 80% within one day,
whereas supplementation with the androgen receptor antagonist,
Casodex, results in time-dependent up-regulation [31]. Casodex is the
commercial name for bicalutamide, an oral, non-steroidal anti-
androgenwidely used in prostate cancer treatment. However, channel
levels are substantially higher in androgen-sensitive LNCaP than
androgen-insensitive PC-3 or DU-145 prostate carcinoma cells [31]
and one hypothesis suggests that TRPV6 expression in LNCaP cells is
regulated by androgen receptors in a ligand-independent manner
[32]. This divergence may be explained by the presence of different
regulatory mechanisms, while the presence of an androgen-respon-
sive element on the 5′ gene ﬂanking sequences requires further
investigation. On the other hand, the trpv6 gene contains an estrogen-
responsive element in the promoter sequence [33]. Estrogens, also
used therapeutically in prostate cancer [34], positively regulate TRPV6
transcription [35]. In that respect, as estrogen is well-known to play an
important role in the development and progression of breast cancer
[36,37], it is not surprising that immunohistological analysis of
mammary adenocarcinoma tissue shows a clear enhancement of
TRPV6 expression compared to normal tissue [38]. Interestingly,
short-term stimulation with estrogen slightly reduces RNA transcrip-
tion of TRPV6, which is enhanced by long-term treatment [39].
Accordingly, blocking the estrogen receptor with Tamoxifen reduces
TRPV6 transcription. Tamoxifen, sold under the trade names Nolva-dex, Istubal, and Valodex, constitutes an orally active, selective,
estrogen-receptor modulator, widely used in treating breast cancer.
Limited estrogen receptor signaling apparently leads to lower TRPV6
expression [39]. These observations suggest that the estrogen receptor
regulates TRPV6 expression. Subsequently, Ca2+ entry via the channel
increases the rate of Ca2+-dependent cell proliferation and is, thus,
directly linked to tumor growth [40]. It is worth noting that recent
results demonstrate a non-genomic effect of estrogens on Ca2+ inﬂux
via TRPV6, whereas 17β-estradiol exerts a rapid, speciﬁc action on the
channel [41]. This indicates that the intratumoral biosynthesis and
accumulation of estrogens in breast carcinoma [36,37] may have a
direct action on TRPV6 other than transcriptional regulation of the
channel, rapidly promoting Ca2+-dependent proliferation. Alterna-
tively, the estrogen-induced Ca2+ inﬂux via TRPV6 may operate
synergistically with estrogen and amplify the channel transcription,
since Ca2+-responsive elements are likely to be present in addition to
the identiﬁed estrogen response elements in the TRPV6 promoter
regions [33]. Several Ca2+-sensitive transcriptional regulators have
been proposed, including the serum responsive element and the
cAMP/Ca2+-responsive element [42,43].
3. Regulation by growth factors
Biochemically, cancer progression also associates the deregulation
of speciﬁc growth factors with their respective signaling pathways
[44–46]. Growth factors may promote or inhibit proliferation, or else
induce apoptosis. In addition, angiogenic growth factors are required
to build the vascular and oxygen supplies necessary for tissue growth
and survival [46]. Here we will only present those growth factors
relevant to the modulation of TRP expression/activity during
oncogenesis.
The hepatocyte growth factor/scatter factor (HGF/SF), also known
as plasminogen related growth factor-1 (PRGF-1), binds to the
tyrosine kinase Met receptor [47,48] and modulates Ca2+ entry and
mobilization [49,50]. The ligand–receptor pair supports the growth of
many epithelial cells in vitro and stimulates invasive growth in
virtually every body tissue [47,48]. HGF/SF promotes cell migration by
stimulating the activity of two TRP members: TRPV1 in human
hepatoblastoma cells [51] and TRPM8 in human glioblastoma cells
[52]. In both cases agonist stimulation, with capsaicin and menthol,
respectively, stimulates Ca2+ inﬂux and cell migration. Their impact
on Ca2+ inﬂux andmigration is enhanced by pre-treatmentwith HGF/
SF [48,52,53]. Thus, TRPV1 and TRPM8 may mediate, at least partly,
the action of HGF/SF in increasing intracellular Ca2+ and promoting
tumor invasion in hepatoblastoma and glioblastoma, respectively,
probably by triggering the early response of a signaling cascade that
gives rise to cell locomotion and the migratory phenotype.
Besides its effect onmigration, HGF/SF induces cell proliferation. In
human hepatoma cells, HGF/SF, together with the endothelial growth
factor (EGF), up-regulate the expression of another TRP member,
TRPC6. The increase in TRPC6 expression results in a rise in Ca2+ entry
and, subsequently, up-regulation of the cell proliferation rate [54]
Indeed, TRPC6 activation in human prostate cancer epithelial cells is
known to trigger the Ca2+-dependent transcription factor and nuclear
factor of activated T cells (NFAT), as well as promote proliferation [17].
Further, the insulin-like growth factor 1 (IGF-1) promotes
progression through the G1 phase of the cell cycle in several cell
types, as well as playing a critical part in tumorigenesis [55]. Like HGF/
SF, IGF-1 stimulates Ca2+ entry. Inhibition of Ca2+ entry blocks the
growth-promoting effect of IGF-1 [56]. IGF-1 enhances Ca2+ inﬂux in
TRPV2-transfected cells by promoting its translocation from intracel-
lular pools to the plasma membrane [57]. Interestingly, TRPV2 [58], as
well as IGF-1 [59] and its receptor [60], are over-expressed in bladder
cancer. Increased proliferation and survival of human bladder smooth-
muscle cells induced bymechanical stress is associated with increased
IGF-1 levels [59]. It is, therefore, possible that the IGF-1/IGF-1R
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growth and progression, via activation of the TRPV2 channel.
Moreover, tumor angiogenesis is a crucial step in cancer develop-
ment, as tumors have to establish a blood supply in order to grow and
metastasize. The tumor microenvironment produces pro-angiogenic
growth factors, such as vascular endothelial growth factor (VEGF) and
platelet-derived growth factor (PDGF) [61]. VEGF acts through the
VEGF receptor with pleiotropic downstream effects, including:
angiogenesis, vascular permeability, enhancement of cell motility,
and inhibition of apoptosis [62–66]. Both of these growth factors
regulate the TRPC6 channel. VEGF increases intracellular Ca2+
concentrations, which modulate microvessel permeability via store-
independent TRPCs and, in particular, TRPC6, in both frogs [67] and
humans [68]. Similarly, PDGF mediates up-regulation of TRPC6
expression and, probably, also its function [69]. The PDGF-mediated
increase in TRPC6 transcription, associated with c-Jun/STAT3, results
in pulmonary artery smooth-muscle cell proliferation [70]. Taking into
account the TRPC6 up-regulation in breast cancer [71] and the role of
the aforementioned pro-angiogenic growth factors in channel
expression and activity, it is intriguing to investigate the putative
role of this channel in cancer progression.
4. Modulatory TRP isoforms
Beyond the simple up- and down-regulation of the expression of
a particular TRP channel gene by hormones and growth factors,
alternative splicing enables the same gene to generate multiple
mature mRNA types for translation, resulting in multiple channel
proteins. The changes in the TRPs involved in cancer on the protein
level are summarized in Fig. 2. This leads to functional diversity,
which, in turn, may have consequences for cellular function.
Alternative splicing generates protein isoforms with different
biological properties, such as a change in functionality, protein/
protein interaction, or subcellular localization [72]. Many of the
splice variants are not functional and may not even be efﬁciently
translated, so they may be considered negligible populations of
incomplete or aberrantly spliced transcripts. Nevertheless, alterna-
tive splicing, as a regulatory process, contributes to biological
complexity, not only by proteome expansion, but also through its
ability to control the expression of functional proteins. This may be
achieved by producing nonfunctional isoforms of the gene by
altering the domains necessary for TRP channel opening, membrane
localization, or association.Fig. 2. Schematic representation of TRP isoforms expressed in cancer. Alternative splicing of
change in functionality, protein/protein interaction, or subcellular localization. Depicted he
TRPM1 in melanoma and TRPM8 in prostate cancer. Alteration in the amino acid level com
sequence (aa: amino acids).TRP proteins form tetrameric channel complexes and at least the
closely related members of one subfamily are capable of building
heteromeric channels [15]. The diversity of native TRP related
channels might be considerably increased by combining different
TRP channel subunits to build a common ion-conducting pore. There
is growing evidence that transcriptional regulation and alternative
mRNA processing also contributes to the diversity of TRP channels.
TRPs are expressed in two or more short splice variants, which may
also exhibit different expression proﬁles in cancer than the full-length
forms. This is the case of TRPV2, which expresses two transcripts in
normal human urothelial cells and bladder tissue specimens: full
length TRPV2 and a short-splice variant, s-TRPV2. Analysis of TRPV2
gene and protein expressions in distinct superﬁcial and invasive
grades and stages indicates that TRPV2 mRNA increases gradually at
increasing grades and stages, while s-TRPV2 expression gradually
decreases [58]. Caprodossi et al. suggested that the differences
observed in the short/full TRPV2 form ratio during tumorigenesis
implied that s-TRPV2 was lost as an early event in bladder
carcinogenesis, whereas the enhanced expression of full-length
TRPV2 in high-stage muscle-invasive urothelial cancer is a secondary
event. In a similar study, a different s-TRPV2, lacking the pore-forming
region and the ﬁfth and sixth transmembrane domains, was
characterized in human macrophages [73]. As for TRPV1 [74], these
naturally occurring alternative splice variants may act as dominant-
negative mutants by forming an heterodimer with TRPV2 and
inhibiting its trafﬁcking and translocation to the plasma membrane.
Concerning TRPV1, the short isoform (TRPV1β) is produced by
alternative splicing of the trpv1 gene, with 10 amino acids missing
near the end of the cytoplasmic N terminus [74]. TRPV1β does not
form a functional channel when it is heterologously expressed alone,
but exerts a dominant-negative effect on TRPV1 when they are co-
expressed. Stability is affected when TRPV1 β is assembled with the
full-length channel, making less TRPV1 protein available at the plasma
membrane. The residual amount of TRPV1 β on the plasmamembrane
is not activated by factors known to stimulate TRPV1, but there are two
other possibilities [74]. Either the residual proteins are not properly
assembled into tetrameric channels or channels that contain TRPV1β
subunits cannot be opened. It should be noted, however, that TRPV1
western blot analysis of the urothelium revealed two bands of equal
intensity at 100 and 95 kDa, which decreased as the cancer progressed
[75]. Further investigation is required to determine whether these are
the two splice TRPV1 isoforms and analyze their expression regulation
as cancer progresses. A similar mechanism is present in normal andTRP channels results in protein isoforms with different biological properties, such as a
re are the changes at the protein level of TRPV1 and TRPV2, involved in bladder cancer,
prises shortened proteins (TRPM1-S) or deletion of small fragments within the whole
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along with some shorter products [20,76]. Heterologous co-expres-
sion of the full-length and short TRPM1 isoforms results in retention
of the full-length channel in the ER [12]. However, it is currently
unclear whether TRPM1 expression in metastasizing lines inhibits
their growth. Metastatic melanomas lack the full-length transcript,
but express several short fragments of TRPM1 [20,76], probably due to
proteolysis of the full length protein [77].
Likewise, TRPM8 also encodes for splice variants, comprising an
altered N terminus cloned from lung epithelia [78] and cancerous
prostate [79]. The lung epithelia splice variant localizes preferentially
to the ER and its activation controls cell responses to cold air-induced
inﬂammation [78,80]. It has not yet been clariﬁed whether this newly
identiﬁed variant is implicated in cancer, whereas it may constitute a
regulatorymechanism for the full-length TRPM8 in tissues where they
both localize, such as liver, colon, and testis [78]. Little information is
available concerning the cancerous prostate TRPM8 isoform. It has a
truncated N terminus [79] and may serve as a dominant negative
regulator of full-length TRPM8, as suggested for TRPM1 truncated
variants [12]. Furthermore, a recent study by Prevarskaya et al.
identiﬁed two TRPM8 isoforms with different androgen sensitivity
and distinct localization on the plasma and ER membrane [10]. This
differential regulation of TRPM8 activity may be due to complex
regulation of the two isoforms by androgen receptors: An alternative
trpm8 gene promoter may make the ER TRPM8 isoform less sensitive
to androgens. However, this ER localization may also result from a
variation in the primary sequence leading to the appearance of an ER
retention signal or the implication of other associated proteins
affecting its trafﬁcking. It should be noted that there is a controversy
in the literature concerning the localization of ER TRPM8. Two studies
proposed a TRPM8-independent ER Ca2+ releasemechanism in LNCaP
[81] and PC3 [82] cells when using high doses of menthol (3 mM [81])
versus the ER TRPM8 activation with 100–250 μM menthol [11,24]).
Furthermore, immunocytochemistry experiments in LNCaP revealed
contradictory results concerning the presence of TRPM8 on the ER
[11,81]. Two scenarios may explain this incongruity: ﬁrstly, as TRPM8
is under androgenic control, culture conditions of LNCaP cells with a
different serummay be critical for channel expression and localization
and, secondly, the putative ER TRPM8 isoform is not necessarily
detected by the different antibodies. In any case, the presence of the
ER TRPM8 was demonstrated in freshly-isolated primary epithelial
prostate cancer cells [10]. Consequently, to clarify whether TRPM8
localizes into the ER, it is necessary to clone this putative ER-speciﬁc
TRPM8 isoform and identify its distinguishing features, as compared
to the two previously cloned variants.
Thus, abundant short or long mRNAs in some cancers arise from a
regulatory mechanism that produces either spliced or partially
degraded non-productive RNAs. These spliced transcripts form
multimers and regulate targeting to the plasma or ER membrane
and, consequently protein activity. Changes in TRP localization may
have a causal or promoting role in cancer. For instance, increases in
constitutively active channels, such as TRPV6, in the plasma
membrane of prostate cancer cells [19,31] may augment Ca2+ in the
cytosol, thus promoting Ca2+-dependent proliferative pathways. The
same may hold true for TRPM1 in melanocytes [12,20,76], since Ca2+
imaging experiments on transfected HEK cells revealed an increase in
intracellular Ca2+ concentrations in comparison to the non-trans-
fected cells [12]. However in the absence of electrophysiological data it
would be premature to conclude that TRPM1 is a constitutively active
channel. Alternatively, altered expression of the channels localizing on
the internal stores, such as the membranes of the ER may be an
adaptive response or may offer a survival advantage, such as
resistance to apoptosis. In that respect, the decrease in urothelial
TRPV1 [75] and prostatic TRPM8 [11,25] in intracellular stores in
aggressive tumors probably reduces the Ca2+ release content and
confers resistance to apoptosis.5. Perspectives
As indicated above, the organization of TRP proteins in space over
time plays an important role in their functionality. Another mechan-
ism that may explain the link between some TRP channels and tumor
development is the physical interaction with proteins involved in the
channel's plasma membrane targeting. For instance TRPV6 cell-
surface localization is regulated by the heterotetrameric complex
S100A10/Annexin 2 [83]. As previously mentioned, TRPV6 is up-
regulated in breast cancer [38], while the S100A10 protein is down-
regulated [84]. The questions arising from these data are: Is the TRPV6
channel properly expressed in the plasma membrane in breast
cancer? How does this change its function? And if not, what other
proteins have replaced S100A10? In view of the growing research ﬁeld
characterizing TRP channel regulation by partner proteins (for
reviews [85–87]), it would be of great interest to investigate cancer-
related TRP-associated proteins using the various screening strategies,
e.g. biochips or two-hybrid systems. Further clariﬁcation of the precise
physiological regulatory mechanisms of TRPs will be vital in
addressing the role of these channels in tumor genesis andmetastasis.
Furthermore, over the past decade, an increasing set of data has
revealed that changes in TRP expression are associated with cancer
development and metastasis. It has been suggested that some TRP
channels may serve as prognostic or diagnostic markers. Indeed,
TRPM1 has been suggested to be a tumor suppressor and a decrease in
TRPM1 expression appears to be a prognostic marker for metastasis in
patients with localized malignant melanoma [20,76]. Similarly, up-
regulated TRPM8 and TRPV6 expression in prostate cancer may
constitute new diagnostic markers for that disease [18,19,88]. Progress
is required, not only in characterizing TRP expression, activity, and
distribution in speciﬁc cancers, but also in addressing the genuine
feasibility of these proteins as drug targets. This will require new
approaches to characterize some channels so that not only their
expression, but also their activity, may be precisely modulated by
highly selective pharmacological agents. This area of research is
particularly signiﬁcant, as the potential for the pharmacological
modulation of channels is one of the key advantages over other
targets, which may be restricted to short interfering RNA or gene
therapy approaches. Finally, the development of humanized inhibitory
antibodies to extracellular domains of TRP channels identiﬁed as
cancer targets may also expand. TRP channels may, therefore, be
anticancer targets as well as useful biomarkers for cancer prognosis
and treatment.
6. Conclusion
This article discussed how TRP channel expression was altered by
hormones and growth factors, as well as the way in which TRP
isoforms may affect intracellular channel localization and functional
alterations during tumorigenesis. Concerning this recently character-
ized, regulatory function of TRP isoforms, it is crucial to determine
the subset of native TRP variants expressed in a speciﬁc kind of
tumor cell in order to understand their physiological role. Hitherto,
little is known about alternative TRP transcripts. Some variants have
already been identiﬁed but there are presumably more. Some of
them may only be accidental, with unknown signiﬁcance. Therefore,
future studies should initially determine whether alternative
transcripts are abundant and if the encoded proteins are really
present in the cell to facilitate an appreciation of their physiological
relevance.
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